ondansetron has been researched along with Glial Cell Tumors in 9 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| " K(+)-flux response mechanisms to the antiemetics ondansetron and granisetron were therefore correlated to malignant glioma cell (Mg251) volume response to estramustine phosphate (EMP) in vitro." | 7.71 | Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. ( Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Sandström, PE, 2002) |
| "A technique of microscopy with computerised detection of early morphological changes during continuous perifusion was used to monitor the geometry changes of cultured glioma cells (MG-251) when exposed to 40 mg/L estramustine phosphate (EMP) alone or in combination with granisetron (0." | 7.70 | Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. ( Behnam-Motlagh, P; Engström, KG; Grankvist, K; Henriksson, R, 1999) |
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 7.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| " K(+)-flux response mechanisms to the antiemetics ondansetron and granisetron were therefore correlated to malignant glioma cell (Mg251) volume response to estramustine phosphate (EMP) in vitro." | 3.71 | Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. ( Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Sandström, PE, 2002) |
| "A technique of microscopy with computerised detection of early morphological changes during continuous perifusion was used to monitor the geometry changes of cultured glioma cells (MG-251) when exposed to 40 mg/L estramustine phosphate (EMP) alone or in combination with granisetron (0." | 3.70 | Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. ( Behnam-Motlagh, P; Engström, KG; Grankvist, K; Henriksson, R, 1999) |
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 3.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| "The effect of a novel 5-HT3 receptor antagonist, BRL 46470, has been studied on two electrophysiological models for 5-HT3 receptors: grease-gap recordings from rat isolated vagus nerve and whole-cell patch-clamp recordings from mouse neuroblastoma-rat glioma NG108-15 cells." | 3.68 | BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. ( Blackburn, TP; Grahame-Smith, DG; Leslie, RA; Newberry, NR; Sprosen, TS; Watkins, CJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rosen, T | 1 |
| Seeger, TF | 1 |
| McLean, S | 1 |
| Nagel, AA | 1 |
| Ives, JL | 1 |
| Guarino, KJ | 1 |
| Bryce, D | 1 |
| Furman, J | 1 |
| Roth, RW | 1 |
| Chalabi, PM | 1 |
| Patel, MP | 2 |
| Woodring, S | 1 |
| Randazzo, DM | 1 |
| Friedman, HS | 1 |
| Desjardins, A | 1 |
| Healy, P | 1 |
| Herndon, JE | 2 |
| McSherry, F | 1 |
| Lipp, ES | 1 |
| Miller, E | 1 |
| Peters, KB | 1 |
| Affronti, ML | 2 |
| Morio, K | 1 |
| Watanabe, J | 1 |
| Tsujimoto, Y | 1 |
| Behnam-Motlagh, P | 2 |
| Sandström, PE | 1 |
| Henriksson, R | 2 |
| Grankvist, K | 2 |
| Kidd, FJ | 1 |
| Levy, JC | 1 |
| Nielsen, M | 1 |
| Hamon, M | 1 |
| Gozlan, H | 1 |
| Barnes, JM | 1 |
| Barnes, NM | 1 |
| Newberry, NR | 1 |
| Watkins, CJ | 1 |
| Sprosen, TS | 1 |
| Blackburn, TP | 1 |
| Grahame-Smith, DG | 1 |
| Leslie, RA | 1 |
| Engström, KG | 1 |
1 trial available for ondansetron and Glial Cell Tumors
| Article | Year |
|---|---|
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
8 other studies available for ondansetron and Glial Cell Tumors
| Article | Year |
|---|---|
Synthesis, in vitro binding profile, and central nervous system penetrability of the highly potent 5-HT3 receptor antagonist [3H]-4-(2-methoxyphenyl)-2-[4(5)-methyl-5(4)-imidazolylmethyl]thiazole.
Topics: Animals; Blood-Brain Barrier; Brain; Chemical Phenomena; Chemistry; Glioma; Imidazoles; Mice; Molecu | 1990 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Size; Estramustine; Glioma; Granisetron; Hu | 2002 |
Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues.
Topics: Aged; Aged, 80 and over; Animals; Benzamides; Binding Sites; Brain; Bridged Bicyclo Compounds; Bridg | 1993 |
Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Topics: Animals; Benzamides; Biguanides; Binding Sites; Binding, Competitive; Bridged Bicyclo Compounds; Bri | 1993 |
BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.
Topics: Animals; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Electrophysiology; Glio | 1993 |
Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells.
Topics: Cell Size; Drug Combinations; Drug Interactions; Estramustine; Glioma; Granisetron; Humans; Ondanset | 1999 |